The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Significance of meflin-positive cancer-associated fibroblasts in predicting response to immune checkpoint inhibitors in non-small cell lung cancer.
 
Yuki Miyai
No Relationships to Disclose
 
Atsushi Enomoto
No Relationships to Disclose
 
Yuichi Ando
Honoraria - AstraZeneca; Bayer Holding; Bristol-Myers Squibb; Celltrion; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Merck Serono; Nippon Kayaku; Novartis; Novartis; Ono Pharmaceutical; Otsuka; Roche; Sawai Pharmaceutical Co; Shionogi; Taiho Pharmaceutical; Tsumura & Co.; Yakult Honsha
Consulting or Advisory Role - ICON Clinical Research; Ono Pharmaceutical; Sun Pharma; SymBio Pharmaceuticals
Research Funding - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Mochida Pharmaceutical Co. Ltd.; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Masahide Takahashi
No Relationships to Disclose